Centru De Evaluare Si Tratament A Toxicodependentelor Pentru Tineri Sf. Stelian
- Address
- lock Available on a paid plan
Behavioral Disciplines and Activities
The Centru De Evaluare Si Tratament A Toxicodependentelor Pentru Tineri Sf. Stelian conducts research that examines how targeted behavioral strategies can improve outcomes for patients with serious psychiatric conditions such as schizophrenia, bipolar I disorder, and major depressive disorder.
- Adjunctive treatments for schizophrenia
- Management of mania and mixed features in bipolar disorder
- Strategies to reduce agitation in Alzheimer’s dementia
- Relapse prevention for depression with anhedonia
- Long‑term safety assessments of novel psychotropic agents
With 13 active studies and a team of seven investigators, the site offers a comprehensive platform for evaluating new therapies and behavioral interventions in a real‑world clinical setting.
Mental Disorders
Research at this Bucharest hospital focuses on the core mental disorders that affect young adults, including schizophrenia, bipolar I disorder, and major depressive disorder. The goal is to test innovative drugs and combination regimens that may provide faster relief and better long‑term stability.
- Efficacy of new antipsychotics for treatment‑resistant schizophrenia
- Acute and maintenance therapy for bipolar mania
- Adjunctive antidepressant strategies for moderate‑to‑severe anhedonia
- Treatment of psychosis associated with Alzheimer’s disease
- Safety monitoring of long‑term adjunctive therapies
The program integrates clinical expertise with rigorous trial design, aiming to expand therapeutic options for patients struggling with severe mental illness.
Psychological Phenomena
Studies under the Psychological Phenomena umbrella explore specific symptom clusters such as anhedonia and agitation, seeking to understand how these experiences impact overall disease burden and treatment response.
- Assessing relapse risk linked to anhedonia in depression
- Measuring agitation levels in Alzheimer’s dementia
- Evaluating behavioral and psychological symptoms of schizophrenia
- Investigating mood stabilization in bipolar patients with mixed features
- Long‑term tolerability of novel agents addressing psychological symptoms
By linking symptom‑focused outcomes with broader clinical endpoints, the site contributes valuable insights that may guide personalized treatment strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Neurocrine Biosciences Inc.4active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Neurocrine Biosciences Inc.6trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centru De Evaluare Si Tratament A Toxicodependentelor Pentru Tineri Sf. Stelian
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults with Schizophrenia | Neurocrine Biosciences Inc. | Phase III | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE | 2 | Unknown | 2025-10-07 | 2025-10-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.